SLC5A2 and heart failure: Although due to the development of sodium-glucose cotransporter 2 inhibitors (iSGLT2) and glucagon-like peptide 1 analogues (aGLP1), the evidence on heart failure in T2D is growing and extensive, in T1D there is a paucity of data.